Get the Stockscreener App
56.03
2.08%
1.14
After Hours:
55.90
-0.13
-0.23%
Exact Sciences Corp stock is traded at $56.03, with a volume of 1.33M.
It is up +2.08% in the last 24 hours and down -0.30% over the past month.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
See More
Previous Close:
$54.89
Open:
$55.34
24h Volume:
1.33M
Relative Volume:
0.53
Market Cap:
$10.37B
Revenue:
$2.69B
Net Income/Loss:
$-214.04M
P/E Ratio:
-47.89
EPS:
-1.17
Net Cash Flow:
$98.43M
1W Performance:
+1.63%
1M Performance:
-0.30%
6M Performance:
+20.29%
1Y Performance:
-14.69%
1-Day Range:
$55.11
$56.74
1-Week Range:
$53.61
$57.26
52-Week Range:
$40.62
$79.62
Exact Sciences Corp Stock (EXAS) Company Profile
Name
Exact Sciences Corp
Sector
Industry
Phone
608-284-5700
Address
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
56.03 | 10.37B | 2.69B | -214.04M | 98.43M | -1.17 |
|
TMO
Thermo Fisher Scientific Inc
|
606.74 | 232.08B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
223.08 | 160.42B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
151.38 | 42.01B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
201.78 | 36.62B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
423.99 | 34.72B | 3.84B | 866.24M | 792.60M | 10.37 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-25 | Initiated | Barclays | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Jan-02-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Aug-02-23 | Downgrade | The Benchmark Company | Buy → Hold |
| May-10-23 | Upgrade | Craig Hallum | Hold → Buy |
| May-05-23 | Initiated | UBS | Neutral |
| Mar-09-23 | Upgrade | Citigroup | Neutral → Buy |
| Feb-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-19-22 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Nov-03-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jul-29-21 | Reiterated | BTIG Research | Buy |
| Jul-29-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-29-21 | Reiterated | Oppenheimer | Outperform |
| Jul-29-21 | Reiterated | Stifel | Buy |
| Jun-15-21 | Initiated | Raymond James | Strong Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Equal Weight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-29-20 | Downgrade | UBS | Buy → Neutral |
| Oct-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Apr-02-20 | Initiated | Evercore ISI | Outperform |
| Jan-10-20 | Resumed | BTIG Research | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Dougherty & Company | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-17-19 | Reiterated | BofA/Merrill | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| Sep-26-19 | Initiated | Oppenheimer | Outperform |
| Feb-26-19 | Upgrade | Goldman | Neutral → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Sep-05-18 | Resumed | The Benchmark Company | Hold |
| Aug-13-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-03-18 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-29-18 | Initiated | Goldman | Neutral |
| Jan-08-18 | Reiterated | The Benchmark Company | Buy |
| Nov-13-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-17 | Downgrade | BTIG Research | Buy → Neutral |
View All
Exact Sciences Corp Stock (EXAS) Latest News
Slow Capital Inc. Grows Stake in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences to launch Oncodetect MRD test in Q2 2025 - MSN
Beacon Investment Advisory Services Inc. Sells 26,980 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Barclays Initiates Coverage of Exact Sciences (EXAS) with Overweight Recommendation - MSN
Assenagon Asset Management S.A. Buys 12,912 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Forecasting The Future: 19 Analyst Projections For Exact Sciences - Benzinga
Barclays sets Exact Sciences stock price target at $70 with Overweight rating - Investing.com
Exact Sciences Q4 EPS Estimate Reduced by Leerink Partnrs - MarketBeat
Exact Sciences (NASDAQ:EXAS) Now Covered by Analysts at Barclays - MarketBeat
Brokers Set Expectations for Exact Sciences FY2026 Earnings - MarketBeat
Leerink Partnrs Lifts Earnings Estimates for Exact Sciences - MarketBeat
Exact Sciences post positive results from MRD trial - Yahoo Finance
Exact Sciences to launch Oncodetect MRD test in Q2 2025 By Investing.com - Investing.com South Africa
Exact Sciences (EXAS): New Evidence Validates Oncodetect's Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients - StreetInsider.com
New Evidence Validates Oncodetect's Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients - Business Wire
Exact Sciences (NASDAQ:EXAS) Trading Up 5%Time to Buy? - MarketBeat
Exact Sciences' Oncodetect MRD Test Shows Breakthrough 91% Cancer Detection Rate in Clinical Trial - StockTitan
Exact Sciences showcases early cancer detection test data at AACR meeting - MSN
Avanza Fonder AB Acquires Shares of 19,512 Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
5,782 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by Retirement Wealth Solutions LLC - MarketBeat
Brookstone Capital Management Decreases Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences (NASDAQ:EXAS) Stock Price Down 4.3%What's Next? - MarketBeat
Why Exact Sciences (EXAS) Is Crashing? - Insider Monkey
Exact Sciences Stock Drops 12% Over Four Days. 'What Is Going On?' - Yahoo! Voices
Beech Hill Advisors Inc. Sells 11,383 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
2 Healthcare Stocks to Buy Hand Over Fist in January - Yahoo Finance
Exact Sciences (NASDAQ:EXAS) Shares Gap UpStill a Buy? - MarketBeat
Exact Sciences (NASDAQ:EXAS) Trading Down 4.3%Here's Why - MarketBeat
William Blair Reaffirms "Outperform" Rating for Exact Sciences (NASDAQ:EXAS) - MarketBeat
Exact Sciences Stock Surges with Strong Financials - TipRanks
Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market - Benzinga
Exact Sciences (NASDAQ:EXAS) Given Buy Rating at Benchmark - MarketBeat
Exact Sciences Boosts Finances and Plans New Launches - TipRanks
Exact Sciences expects Q4 and FY revenue to beat estimates - MSN
Exact Sciences Reports 10% Revenue Jump to $713M, Plans Three New Cancer Tests for 2025 - StockTitan
Exact Sciences Announces Preliminary Fourth Quarter 2024 Results - Yahoo Finance
Exact Sciences Co. (NASDAQ:EXAS) Shares Acquired by Harbor Capital Advisors Inc. - MarketBeat
Q2 EPS Estimate for Exact Sciences Increased by Analyst - MarketBeat
Should Exact Sciences Stock Stay in Your Portfolio Right Now? - Yahoo Finance
Exact Sciences Co. (NASDAQ:EXAS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Exact Sciences Corporation Announces Appointment of Kim Popovits as A Class I Member of the Board - Marketscreener.com
Exact Sciences to participate in J.P. Morgan Healthcare Conferen - GuruFocus.com
Exact Sciences price target raised to $70 from $60 at Evercore ISI - Yahoo Finance
Exact Sciences to Participate in J.P. Morgan Healthcare Conference - Marketscreener.com
Exact Sciences to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Exact Sciences Announces Second-Quarter 2023 Results - GuruFocus.com
Exact Sciences Co. (NASDAQ:EXAS) Short Interest Down 5.3% in December - MarketBeat
(EXAS)Analyzing Exact Sciences's Short Interest - Benzinga
Exact Sciences Corporation's (NASDAQ:EXAS) Shift From Loss To Profit - Simply Wall St
Principal Financial Group Inc. Has $71.48 Million Stock Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Tidal Investments LLC Grows Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Corp Stock (EXAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):